<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Freestyle on 0x000216</title><link>https://Nexus-Security.github.io/tags/freestyle/</link><description>Recent content in Freestyle on 0x000216</description><language>en</language><lastBuildDate>Mon, 19 Dec 2022 10:51:45 +0000</lastBuildDate><atom:link href="https://Nexus-Security.github.io/tags/freestyle/index.xml" rel="self" type="application/rss+xml"/><item><title>Abbott introduces the Freestyle Libre Pro System for glucose monitoring in India</title><link>https://Nexus-Security.github.io/abbott-introduces-the-freestyle-libre-pro-system-for-glucose-monitoring-in-india/</link><pubDate>Mon, 19 Dec 2022 10:51:45 +0000</pubDate><guid>https://Nexus-Security.github.io/abbott-introduces-the-freestyle-libre-pro-system-for-glucose-monitoring-in-india/</guid><description>Research from the Asia Diabetes Foundation (ADF) indicates a growing trend of type II diabetes among young adults in Asia. A collaborative study by the ADF and Merck, called the Joint Asia Diabetes Evaluation (JADE), revealed that 18% of participants from nine Asian countries and territories were diagnosed with diabetes before the age of 40. This condition is known as young-onset diabetes.
While pharmaceutical company Merck offers the drug Janumet XR for type II diabetes treatment, healthcare company Abbott takes a different approach...<p>Read The Full Article :<a href="https://Nexus-Security.github.io/abbott-introduces-the-freestyle-libre-pro-system-for-glucose-monitoring-in-india/">https://Nexus-Security.github.io/abbott-introduces-the-freestyle-libre-pro-system-for-glucose-monitoring-in-india/</a></p></description></item></channel></rss>